openPR Logo
Press release

Zhonghan Biotech's Abemaciclib Intermediates: High-Quality Key Intermediates Empowering Efficient Synthesis of CDK4/6 Inhibitors

03-18-2026 08:32 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Zhonghan Biotech's Abemaciclib Intermediates: High-Quality

As an orally highly selective CDK4/6 inhibitor [https://www.xsu.com/n-isopropylacetamide-cas-1118-69-0-product/], Abemaciclib is a core targeted drug for the treatment of HR+/HER2- breast cancer, widely used in the clinical treatment of locally advanced and metastatic breast cancer. Its synthesis chain has stringent requirements for the purity, stability and batch consistency of key intermediates, which directly determine the quality of active pharmaceutical ingredients (APIs) and the safety of preparations.

Jinan Zhonghan Chemical Technology Co., Ltd. focuses on the R&D and large-scale production of high-end pharmaceutical intermediates. Relying on mature processes, strict quality control and customized production capacity, we have launched a series of high-purity key intermediates for Abemaciclib, covering key nodes of core skeleton construction and side chain synthesis, providing pharmaceutical enterprises with stable, compliant and cost-effective raw material support

Product Positioning and Core Value

Our Abemaciclib Intermediates [https://www.xsu.com/abemaciclib-intermediates-1/] are positioned to meet the needs of commercial API production, with the core advantages of high purity, low impurities, stable process and scalability. They are suitable for the whole process from laboratory small-scale test to industrial mass production, helping customers shorten R&D cycles, reduce production costs, and improve pharmaceutical compliance and market competitiveness.

Image: https://www.abnewswire.com/upload/2026/03/535cbfda0eda36c1a0c907ad5691f72b.jpg

Core Intermediates and Key Indicators

- 4-Bromo-2,6-difluoroaniline

CAS: 67567-26-4

Purity greater than or equal to 99.5%, single impurity less than or equal to 0.1%. Moisture and metal residues are strictly controlled. It is suitable for cyclization and coupling reactions with stable yield.

- N-Isopropylacetamide

CAS: 1118-69-0

As a key building block for amidination and cyclization, it features high purity and controllable impurities, supports continuous processes and improves the overall yield.

- Other Customized Intermediates: We provide one-stop services including custom development, process optimization and pilot scale-up according to customers' synthetic routes, meeting the needs of patent circumvention and differentiated synthesis.

Image: https://www.abnewswire.com/upload/2026/03/7bbbed271543443fa06ac12d684db105.jpg

Technical and Quality Advantages

* Mature and Stable Process: Adopting optimized synthetic routes with mild reaction conditions, few by-products and compliant three-waste treatment, suitable for continuous production.
* Stringent Quality System: Implementing the ISO9001 quality management system, establishing a full-item detection and traceability system for genotoxic impurities, heavy metals, residual solvents, etc., with strong batch consistency.
* Reliable Delivery Guarantee: Combining standardized production with flexible capacity, providing stable supply from gram-level to ton-level, supporting rapid response and long-term price locking.
* Professional Technical Support: Equipped with a professional R&D and technical service team, providing supporting services such as process parameters, post-treatment and purification schemes.

Application Scenarios

Our products are targeted at domestic and foreign API manufacturers, CDMO/CMO and innovative drug R&D institutions, used for the synthesis, process verification, registration application and commercial production of Abemaciclib API, fully meeting the compliance requirements of China NMPA, US FDA, EU CEP and other regulatory authorities.

About Zhonghan Biotech

Jinan Zhonghan Chemical Technology Co., Ltd. specializes in the R&D and preparation of high-value-added new drug intermediates and active small molecule inhibitors, focusing on therapeutic fields such as anti-tumor and cardiovascular diseases, integrating R&D, pilot test, production and sales. With modern production workshops, a professional R&D platform and a number of invention patents, the company adheres to the philosophy of innovation-driven, quality-oriented and customer-first, and continuously provides reliable raw materials and technical solutions for the global pharmaceutical industry.

Business and Technical Enquiry

For product COA, spectra, quotation and custom development solutions, please contact us:

Tel: [18562151612]

Email: [2289008634@qq.com]

Official Website: https://www.xsu.com/

Media Contact
Company Name: Jinan Zhonghan Chemical Technology Co., LTD.
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=zhonghan-biotechs-abemaciclib-intermediates-highquality-key-intermediates-empowering-efficient-synthesis-of-cdk46-inhibitors]
Country: China
Website: http://www.xsu.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Zhonghan Biotech's Abemaciclib Intermediates: High-Quality Key Intermediates Empowering Efficient Synthesis of CDK4/6 Inhibitors here

News-ID: 4430355 • Views:

More Releases from ABNewswire

How to adjust the air intake of a jet aerator according to water quality?
How to adjust the air intake of a jet aerator according to water quality?
The air intake of a jet aerator should be dynamically adjusted based on the influent water quality indicators (such as COD, BOD, and ammonia nitrogen concentration) to match the oxygen demand for microbial degradation of organic matter and nitrification. When the water concentration is high, the air intake should be increased; when the concentration is low, it should be decreased to avoid over-aeration leading to energy waste or under-aeration resulting
Recademics.com Launches New York Boater Safety Course
Recademics.com Launches New York Boater Safety Course
Approved by the New York State Parks and aligned with NASBLA standards, the Recademics boater safety course provides a convenient, interactive way for New York residents and visitors to learn safe boating practices and meet New York's boater education expectations. Southlake, TX - Recademics.com, a U.S.-based provider of online recreational safety certification courses, is proud to announce the launch of its New York Boater Safety Course. Approved by the New York
Recademics.com Launches New York Boater Safety Course
Recademics.com Launches New York Boater Safety Course
Approved by the New York State Parks and aligned with NASBLA standards, the Recademics boater safety course provides a convenient, interactive way for New York residents and visitors to learn safe boating practices and meet New York's boater education expectations. Southlake, TX - Recademics.com, a U.S.-based provider of online recreational safety certification courses, is proud to announce the launch of its New York Boater Safety Course. Approved by the New York
TopOnwardTicket Launches Fast and Reliable Onward Ticket Reservation Service for International Travelers
TopOnwardTicket Launches Fast and Reliable Onward Ticket Reservation Service for …
TopOnwardTicket, a global online travel documentation platform, today announced the launch of its fast and reliable onward ticket reservation service [https://toponwardticket.com/] designed to help international travelers meet visa and immigration requirements quickly and affordably. As international travel continues to grow, many countries require visitors to provide proof of onward travel before entering the country. Immigration authorities and airlines may request confirmation that travelers intend to leave the destination country before the

All 5 Releases


More Releases for Abemaciclib

Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline Expands as 45+ Compani …
DelveInsight's, "Cyclin-Dependent Kinase Inhibitor Pipeline Insights 2025" report provides comprehensive insights about 45+ companies and 52+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the Cyclin-Dependent Kinase Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cyclin-Dependent Kinase Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our
Abemaciclib Market Witnessing High Growth | Demand, Size & Regional Analysis 202 …
The latest report by Coherent Market Insights indicates strong growth potential for the Abemaciclib Market from 2026 to 2033, supported by rising industry demand, expanding applications, and ongoing technological advancements. The study delivers a clear overview of market size, revenue trends, and key growth factors shaping the global landscape. This research analyzes major market drivers, restraints, challenges, and emerging opportunities, while highlighting innovation trends and financial insights influencing competitive strategies.
Abemaciclib Market Share Analysis Across Monotherapy Combination Therapy and Adv …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Abemaciclib Market Size, Share & Trends Analysis Report, By Therapy Type (Monotherapy (Abemaciclib Alone) and Combination Therapy (with Endocrine Therapy, other Cancer Drugs)), By Indication (Early Breast Cancer (HR-positive, HER2-negative), Advanced or Metastatic Breast Cancer (HR-positive, HER2-negative), and Other Cancer Types), By Dosage Strength (50 mg, 100 mg, 150 mg, and 200 mg), By Line
Abemaciclib Market Set to Significantly Grow from 2025 to 2032 |Eli Lilly and Co …
The Global Abemaciclib Market is estimated to be valued at USD 1.94 Bn in 2025 and is expected to reach USD 4.48 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Abemaciclib Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth factors,
Abemaciclib Market Poised to Hit $2.53 Billion by 2029 with Accelerating Growth …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Abemaciclib Market Size Growth Forecast: What to Expect by 2025? In recent times, there has been a speedy increase in the abemaciclib market size. It is anticipated to rise from $1.42 billion in 2024 to $1.60 billion in 2025, with an annual growth rate of 12.5%. The significant expansion
Precision Standards for Oncology Research: Exploring Abemaciclib Impurity 1 and …
In the ever-evolving field of targeted cancer therapy, Abemaciclib has emerged as a pivotal agent in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. As researchers and pharmaceutical developers continue to innovate in oncology, the importance of impurity profiling and the availability of reliable Abemaciclib impurity standards has never been greater. At the forefront of pharmaceutical impurity standards, Aquigen Bio is proud to support global manufacturers, CROs,